KIDNEY STONE MANAGEMENT DEVICES MARKET ANALYSIS

Kidney Stone Management Devices MarketSize and Trends

Urolithiasis is the most frequent and common urological disease, which involves stone formation in the kidney, bladder, and urinary tract. The reasons behind stone development in above mentioned areas are mainly associated with decreased urine volume and increased excretion of stone-forming substances such as oxalate, calcium, cysteine, urate, phosphate, and xanthine. Kidney stones can be treated effectively, due to presence of advanced methods and associated medical devices. According to the American Urologic Association (AUA), direct and associated treatment cost related to kidney stone diagnosis and management has increased over the past few years. Despite recent advancements in therapeutic and surgical treatment techniques, the overall health care expenditure for the kidney stone disease management has increased. According to National Center for Biotechnology Information (NCBI), the cost for medical management of kidney stones is expected to reach to US$ 1.24 Bn annually in the U.S. by 2030. Cost containment for the patients has been made possible by technological development in terms of shorter duration hospital stays and more minimally invasive surgical procedures.

Kidney stones can occur in one or both kidneys. It can affect people between ages of 30 to 60 years according to the National Health Service (NHS). Furthermore, the global prevalence of kidney stones annually is three in 20 men and two in 20 women according to NHS. The U.S. National Health and Nutrition Examination Survey (NHANES), published in 2012, stated that the prevalence of kidney stones in men was 10.6% and was 7.1% in women.

New product launches and ongoing research on prevention and treatment of kidney stones is expected to boost the market growth over the forecast period

Technological advancements and innovative product launches have allowed for therapy optimization and better management of the stones irrespective of their sizes. Terumo Corporation launched GLIDEWAY ureteral access sheath, which was used in minimally invasive urologic procedures in 2014. Boston Scientific launched LithoVue single use digital flexible ureteroscopes in Europe in 2016, which provided high-quality visualization better than leading ureteroscopes at the time.